Science Translator
The SPAGN Science Translator is a new publication series highlighting research findings that are particularly relevant to sarcoma patients and patient advocates. It focuses on emerging treatment approaches, advances in personalised medicine and outcomes that matter to patients.
Through these publications, we aim to make selected scientific research more accessible and explain what the findings could mean for patients, while also highlighting the questions that remain.
-
ESMO Congress 2026: Selected Sarcoma Research Highlights
SPAGN Science Translator | Congress Report Authors: Kathrin Schuster and Bernd Kasper Status: Draft for scientific review The European Society for Medical Oncology (ESMO) is one of the leading professional organisations in cancer care. Its annual congress is among the most important international oncology meetings, bringing together researchers and clinicians to present and discuss new…
-
ASCO 2026: Strong Momentum for Sarcoma Research
By Kathrin Schuster & Bernd Kasper, June 2026 ASCO 2026 was a remarkable year for sarcoma research: The program included several phase III trials, new targeted therapies, cell therapy approaches, translational research, and biomarker-driven strategies, reflecting the continued evolution of the field. Compared with previous years, sarcoma had a particularly visible presence at this year’s…
-
Key Take-Aways for Patients from EMSOS 2026
EMSOS is a leading European society focused on musculoskeletal oncology. Each year, the congress brings specialists together to share the latest insights, treatments, and research results. The 2026 edition took place in Portugal. What also stood out was that the congress was not only about doctors and treating specialists. Researchers, students, psychologists, and other healthcare…
